Epizyme announces first patient dosed in global clinical program evaluating tazemetostat in genetically defined solid tumours
US study sites now enrolling adults in registration-supporting Phase II study.
Epizyme has announced that the first patient has been dosed in the Phase II study of tazemetostat in adult patients with genetically defined tumours. The Phase I dose escalation study in pediatric patients with the same tumour types is also now open for enrollment. The cancers being studied in these trials, INI1-negative tumuors, certain SMARCA4-negative tumours and synovial sarcomas, are aggressive cancers that are poorly served by current treatments. The first sites activated for adult enrollment are Northwestern University, MD Anderson Cancer Center and Cincinnati Children’s Hospital and the first sites activated for pediatric enrollment are the Dana Farber Cancer Institute and Cincinnati Children’s Hospital. Additional study sites in the US, Canada, Europe and Australia are planned to be added over the upcoming months.
"Life-threatening rare tumors such as rhabdoid tumours, epithelioid sarcomas and synovial sarcomas affect children and young adults who are in need of novel effective therapies since the standard approaches are only marginally useful,” said George Demetri, Director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute and Professor of Medicine, Harvard Medical School. “We are enthusiastic about evaluating tazemetostat in our patients with these forms of sarcomas since the molecular mechanism is so compelling, especially with the recent identification of mutations in INI1 or SMARCA4 as genetic drivers for these cancers."
“This important study will enroll children with cancers such as malignant rhabdoid tumour, based on unique genetic defects that appear to result in biological sensitivity to EZH2 inhibition,” said Susan Chi, Director of the Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute and Assistant Professor of Pediatrics, Harvard Medical School. “For children with these deadly diseases, tazemetostat potentially represents a meaningful option when other treatments have been exhausted.”
“Initiation of the clinical program in genetically defined solid tumours is an important milestone for Epizyme and expands tazemetostat development beyond non-Hodgkin lymphoma,” said Peter Ho, Chief Medical Officer, Epizyme. “We are excited to advance the study of tazemetostat in these patients.”
Related News
-
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News A Day in the Life of a Vice President in R&D & Engineering
In the Day in the Life of Series, we've already had the chance to get to know a range of people in various roles in the pharma industry. In the latest interview we get a glimpse into the R&D side of things from Jennifer Sorrells, Vice Presiden...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance